ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.4776C>G (p.Asn1592Lys) (rs761925468)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000162819 SCV000213302 uncertain significance Hereditary cancer-predisposing syndrome 2016-11-01 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence
Color RCV000162819 SCV000683213 uncertain significance Hereditary cancer-predisposing syndrome 2018-10-05 criteria provided, single submitter clinical testing
DNA and Cytogenetics Diagnostics Unit,Erasmus Medical Center RCV000616786 SCV000744609 likely benign Breast-ovarian cancer, familial 1 2015-09-21 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000485047 SCV000591538 uncertain significance not specified 2015-01-19 criteria provided, single submitter clinical testing
Diagnostic Laboratory, Department of Genetics,University Medical Center Groningen RCV000616786 SCV000733606 likely benign Breast-ovarian cancer, familial 1 no assertion criteria provided clinical testing
GeneDx RCV000590715 SCV000567561 uncertain significance not provided 2017-10-26 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.4776C>G at the cDNA level, p.Asn1592Lys (N1592K) at the protein level, and results in the change of an Asparagine to a Lysine (AAC>AAG). Using alternate nomenclature, this variant would be defined as BRCA1 4895C>G. Although this exact nucleotide change has not, to our knowledge, been published in the literature as pathogenic or benign, a different nucleotide change at the same position resulting in the same amino acid change was observed in a cohort of 121 Moroccan breast cancer patients (Laraqui 2013). BRCA1 Asn1592Lys was not observed at a significant frequency in large population cohorts (Lek 2016). Since Asparagine and Lysine differ in some properties, this is considered a semi-conservative amino acid substitution. BRCA1 Asn1592Lys occurs at a position where amino acids with properties similar to Asparagine are tolerated across species and is located in a region known to interact with multiple proteins (Paul 2014). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether BRCA1 Asn1592Lys is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Integrated Genetics/Laboratory Corporation of America RCV000590715 SCV000699175 uncertain significance not provided 2016-03-15 criteria provided, single submitter clinical testing
Invitae RCV000697143 SCV000825739 uncertain significance Hereditary breast and ovarian cancer syndrome 2018-12-27 criteria provided, single submitter clinical testing This sequence change replaces asparagine with lysine at codon 1592 of the BRCA1 protein (p.Asn1592Lys). The asparagine residue is weakly conserved and there is a moderate physicochemical difference between asparagine and lysine. This variant is present in population databases (rs761925468, ExAC 0.009%). This variant has been reported in an individual affected with breast cancer in the Leiden Open-source Variation Database (PMID: 21520333). ClinVar contains an entry for this variant (Variation ID: 183931). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.